Prognosis

The Foundation for Sarcoidosis Research (FSR) awards $100,000 in support of cardiac sarcoidosis

Retrieved on: 
Monday, December 18, 2023
School, Faculty, Duke University Hospital, Partnership, Prognosis, Research, Pathology, Inflammation, Disease, Johns Hopkins University, Doctor of Philosophy, Sarcoidosis, Transplant, Duke University, University, 3D, University of Pennsylvania, Assistant, Diagnosis, Public health, JHU, FSR, Medical device

CHICAGO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Foundation for Sarcoidosis Research (FSR) announces $100,000 in funding for support of research aimed at improving diagnosis, management, and treatment of cardiac sarcoidosis.

Key Points: 
  • CHICAGO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Foundation for Sarcoidosis Research (FSR) announces $100,000 in funding for support of research aimed at improving diagnosis, management, and treatment of cardiac sarcoidosis.
  • With this grant, we aim to improve the specificity of cardiac sarcoidosis diagnosis with FDG-PET using a novel strategy incorporating combined SGLT1/2 inhibition with sotagliflozin.
  • “The 2023 FSR Sarcoidosis Cardiac Grant award will allow us to use the novel 3D multi-omic pathology to determine unique properties of vasculature surrounding cardiac sarcoidosis granulomas and find new potential biomarker targets and histological criteria for cardiac sarcoidosis diagnosis.
  • FSR is dedicated to accelerating sarcoidosis research through fellowships, small grants, large grants, and disease specific grants to advance sarcoidosis research and advance care for those living with sarcoidosis.

TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138

Retrieved on: 
Tuesday, December 12, 2023
RNA, Metastasis, Survival, Transcoding, TTX, Survival rate, Prognosis, Research, Radiation, Therapy, Cancer, Animal, Neoplasm, Pancreatic cancer, PDAC, Patient, Palliative care, Malignancy, Pharmaceutical industry

The study demonstrated that TTX-MC138 was effective against metastatic (stage IV) pancreatic cancer in animal models.

Key Points: 
  • The study demonstrated that TTX-MC138 was effective against metastatic (stage IV) pancreatic cancer in animal models.
  • There are currently no treatment options for patients with metastatic (stage IV) pancreatic cancer beyond palliative care.
  • The study involved weekly injection of TTX-MC138 into animals bearing human pancreatic tumors.
  • Furthermore, the company believes that these results underscore the efficacy of its TTX platform for the systemic delivery of RNA-based therapeutics into solid tumors.

Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

Retrieved on: 
Monday, December 11, 2023
IO, ESMO, Prognosis, Antibody, FDA, FTD, Melanoma, SAN, Congress, Novartis, Neoplasm, MEK, Oncology, NRAS, Patient, Safety, Journal, Binimetinib, Pharmaceutical industry

SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to naporafenib in combination with trametinib (MEKINIST®) for the treatment of adult patients with unresectable or metastatic melanoma who have progressed on, or are intolerant to, an anti‑programmed death-1 (ligand 1) (PD‑(L)1)-based regimen, and whose tumors contain an NRAS mutation (NRASm). Naporafenib is an orally available, Phase 3-ready pan-RAF inhibitor with a potential first-in-class and best-in-class profile in NRASm melanoma and other RAS/MAPK pathway-altered solid tumors.

Key Points: 
  • Naporafenib is an orally available, Phase 3-ready pan-RAF inhibitor with a potential first-in-class and best-in-class profile in NRASm melanoma and other RAS/MAPK pathway-altered solid tumors.
  • “The outcomes for patients with NRASm melanoma after frontline immunotherapy (IO) treatment are dismal with low response rates and short median progression free survival (mPFS).
  • Effective treatment options are needed for patients following progression on frontline IO with anti-CTLA-4 and/or anti-PD-(L)1 antibodies.
  • Erasca recently reported that End of Phase 2 meetings with the FDA and European health authorities confirmed the SEACRAFT-2 Phase 3 trial design and provided clarity on the registrational pathway.

TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition

Retrieved on: 
Saturday, December 9, 2023
Patient, Associate, Immunosuppression, Malignancy, Exposition, Acute leukemia, MRD, Prognosis, TCR, Haematopoietic system, City, Society, Therapy, MDS, Cancer, Infrared spectroscopy correlation table, Conditional sentence, ASH, HCT, Syndrome, Transplant, Acute myeloid leukemia, Safety, Cell, ALL, AML, B-ALL, KOL, Pharmaceutical industry

“We are excited to present initial clinical data in our heme program, with six patients in our treatment arms and four patients in our control arm.

Key Points: 
  • “We are excited to present initial clinical data in our heme program, with six patients in our treatment arms and four patients in our control arm.
  • In contrast, these indicators were not achieved in any of the four control-arm patients.
  • After establishing the recommended Phase 2 dose, we plan to open expansion cohorts at that dose to further characterize safety and evaluate translational and efficacy endpoints.
  • We have designed TSC-100 and TSC-101 to address this unmet need and increase the success rate of transplantation.

Wistar Scientists Identify Esophageal Cancer Biomarkers

Retrieved on: 
Wednesday, December 6, 2023
RNA, Wistar Institute, Ferroptosis, Collaborative writing, RNA-Seq, National Cancer Institute, Biomedical Research, Culture, Mechanics, Tumor microenvironment, Ellen, Virus, ESCA, Messenger, Prognosis, Health, Ageing, Incidence, Neoplasm, Cancer, International Society, University, University of Pennsylvania, Ecology, Gene expression, Gene, Biomarker, Machine learning, Cell, Patient, Qi, Iron, NCI, Bacteriophage, Esophageal cancer, Carnegie Mellon University

Philadelphia, PA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Wistar scientists have developed a new tool that can help identify cancer-associated microbes by using machine learning technology.

Key Points: 
  • Philadelphia, PA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Wistar scientists have developed a new tool that can help identify cancer-associated microbes by using machine learning technology.
  • Under the leadership of Dr. Noam Auslander — assistant professor in the Ellen and Ronald Caplan Cancer Center’s Molecular & Cellular Oncogenesis Program — the group has analyzed short read RNA-sequencing data to detect biomarkers for esophageal carcinoma, or ESCA.
  • Since 1972, the Institute has held National Cancer Institute (NCI)-designated Cancer Center status.
  • Wistar scientists are dedicated to solving some of the world’s most challenging problems in the field of cancer and immunology, advancing human health through early-stage discovery and training the next generation of biomedical researchers.

Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease

Retrieved on: 
Sunday, November 26, 2023
DREAM, Prognosis, FDA, Endothelial dysfunction, Disease, Mortality, Person, Inflammation, Ageing, ODD, Heart, Immunomodulation, Ventricular septal defect, MSB, Growth, Patient, HLHS, Journal, Heart failure, MESO, Pharmaceutical industry

Unfortunately, achievement of this objective is limited by the inability in most patients for the left ventricle to grow sufficiently to support the circulation to the body.

Key Points: 
  • Unfortunately, achievement of this objective is limited by the inability in most patients for the left ventricle to grow sufficiently to support the circulation to the body.
  • The FDA has authority to grant orphan drug (OD) designation to a drug or biological product to prevent, diagnose or treat a rare disease or condition, defined as any disease or condition that affects less than 200,000 persons in the United States.
  • An orphan drug designation (ODD) qualifies sponsors for incentives including tax credits for qualified clinical trials, exemption from user fees, and the potential for seven years of market exclusivity after approval.
  • A rare pediatric disease designation (RPDD) demonstrates that the disease is serious or life-threatening and the manifestations primarily affect individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and adolescents, and that the disease is a rare disease or condition.

International Center for Genetic Disease, Mass General Brigham launches a global Clinical Genomic Medicine and Genetic Counseling training program in United Arab Emirates

Retrieved on: 
Tuesday, November 21, 2023
Hospital, Genetic counseling, Partnership, Medicine, Physician, International Center, Prognosis, Excellency, Trustee, Diabetes, Emirate, Health, Doctor of Philosophy, Khalifa University, Cancer, Mass, Genomics, Knowledge, Genetics, Public, Mass General Brigham, DSM-IV codes, Harvard University, FACMG, Patient, Diagnosis, Risk management, Harvard Medical School, MSHA, Hemoglobinopathy, Pharmaceutical industry

To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling.

Key Points: 
  • To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling.
  • This training program is implemented in collaboration with the Department of Health – Abu Dhabi and Khalifa University of Science and Technology.
  • This initiative is designed to integrate genetics and genomics into patient care effectively, underscoring our dedication to enhancing genomic medicine worldwide.
  • Higgins, MD, MSHA, President of Brigham and Women’s Hospital and Executive Vice President at Mass General Brigham.

International Center for Genetic Disease, Mass General Brigham launches a global Clinical Genomic Medicine and Genetic Counseling training program in United Arab Emirates

Retrieved on: 
Tuesday, November 21, 2023
Hospital, Genetic counseling, Partnership, Medicine, Physician, International Center, Prognosis, Excellency, Trustee, Diabetes, Emirate, Health, Doctor of Philosophy, Khalifa University, Cancer, Mass, Genomics, Knowledge, Genetics, Public, Mass General Brigham, DSM-IV codes, Harvard University, FACMG, Patient, Diagnosis, Risk management, Harvard Medical School, MSHA, Hemoglobinopathy, Pharmaceutical industry

To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling.

Key Points: 
  • To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling.
  • This training program is implemented in collaboration with the Department of Health – Abu Dhabi and Khalifa University of Science and Technology.
  • This initiative is designed to integrate genetics and genomics into patient care effectively, underscoring our dedication to enhancing genomic medicine worldwide.
  • Higgins, MD, MSHA, President of Brigham and Women’s Hospital and Executive Vice President at Mass General Brigham.

International Center for Genetic Disease, Mass General Brigham launches a global Clinical Genomic Medicine and Genetic Counseling training program in United Arab Emirates

Retrieved on: 
Tuesday, November 21, 2023
Hospital, Genetic counseling, Partnership, Medicine, Physician, International Center, Prognosis, Excellency, Trustee, Diabetes, Emirate, Health, Doctor of Philosophy, Khalifa University, Cancer, Mass, Genomics, Knowledge, Genetics, Public, Mass General Brigham, DSM-IV codes, Harvard University, FACMG, Patient, Diagnosis, Risk management, Harvard Medical School, MSHA, Hemoglobinopathy, Pharmaceutical industry

To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling.

Key Points: 
  • To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling.
  • This training program is implemented in collaboration with the Department of Health – Abu Dhabi and Khalifa University of Science and Technology.
  • This initiative is designed to integrate genetics and genomics into patient care effectively, underscoring our dedication to enhancing genomic medicine worldwide.
  • Higgins, MD, MSHA, President of Brigham and Women’s Hospital and Executive Vice President at Mass General Brigham.

International Center for Genetic Disease, Mass General Brigham launches a global Clinical Genomic Medicine and Genetic Counseling training program in United Arab Emirates

Retrieved on: 
Tuesday, November 21, 2023
Hospital, Genetic counseling, Partnership, Medicine, Physician, International Center, Prognosis, Excellency, Trustee, Diabetes, Emirate, Health, Cancer, Doctor of Philosophy, Khalifa University, Mass, Genomics, Knowledge, Genetics, Public, Mass General Brigham, DSM-IV codes, Harvard University, FACMG, Patient, Diagnosis, Risk management, Harvard Medical School, MSHA, Hemoglobinopathy, Pharmaceutical industry

To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling.

Key Points: 
  • To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling.
  • This training program is implemented in collaboration with the Department of Health – Abu Dhabi and Khalifa University of Science and Technology.
  • This initiative is designed to integrate genetics and genomics into patient care effectively, underscoring our dedication to enhancing genomic medicine worldwide.
  • Higgins, MD, MSHA, President of Brigham and Women’s Hospital and Executive Vice President at Mass General Brigham.